All In Biotech

Drug Trial Radar · NCT07806175

A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors

A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 Tablets in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

486

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Aug 15, 2028

Study completion Aug 15, 2029

Sponsor

Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

  • RCZY690 TabletsDrug

    Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.

  • RCZY690 tablesDrug

    Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting ToxicityTime frame: 24 months
  2. Number of subjects with adverse events (AEs)Time frame: 24 months
  3. Maximum Tolerated Dose and/or Maximum Administered DoseTime frame: 24 months
  4. Recommended Phase 2 DoseTime frame: 24 months
  5. Objective Response Rate (ORR)Time frame: 24 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, CAMS

    Beijing, Beijing Municipality, China

  • Hunan Provincial Cancer Hospital

    Hunan, Changsha, China

  • Zhejiang Cancer Hospital

    Zhejiang, Hangzhou, China

  • Shandong Cancer Hospital

    Shandong, Jinan, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Cancer Hospital

    Shanxi, Taiyuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.